NCT02941744View on ClinicalTrials.gov

A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2019

Conditions

Stage IIIC Skin MelanomaStage IV Skin Melanoma

Interventions

DRUG

nivolumab

low fixed dose ipilimumab in combination with nivolumab

DRUG

ipilimumab

low fixed dose ipilimumab in combination with nivolumab

Trial Locations (1)

1090

UZ Brussel, Jette

All Listed Sponsors

lead

Universitair Ziekenhuis Brussel

OTHER

NCT02941744 - A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases | Biotech Hunter | Biotech Hunter